MarketCap
Eli Lilly and Company LLY
€ 1 275.88
1.43%
Facebook
X
Telegram
Eli Lilly and Company Langfristiger Schuldenstrom | LLY
Langfristiger Schuldenstrom Jährlich Eli Lilly and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 222 M | 176 M | 156 M | - | - | - | - | - | - | - | - | - | - | 11.9 M | 1.52 B | 18.2 M | -20.3 M | - | - | - |
Jährliche Entwicklung
Kennzahlen zur Anzeige auswählen
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 1.52 B | -20.3 M | 297 M |
Langfristiger Schuldenstrom anderer Aktien in der Pharmaeinzelhändler
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Repare Therapeutics
RPTX
|
1.84 M | - | - | $ 112 M |  Canada |
 |
Sesen Bio
SESN
|
832 K | - | 7.29 % | $ 127 M |  USA |
 |
Windtree Therapeutics
WINT
|
508 K | - | - | $ 26.8 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
6.56 M | - | 57.95 % | $ 12.8 M | USA |
 |
MEI Pharma
MEIP
|
1.43 M | - | 10.43 % | $ 20.5 M | USA |
 |
Palatin Technologies
PTN
|
158 K | - | - | $ 13 M | USA |
 |
Lyra Therapeutics
LYRA
|
4.82 M | - | - | $ 24.9 M | USA |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
Applied Therapeutics
APLT
|
406 K | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
124 K | - | - | $ 8.86 M | Canada |
 |
Generation Bio Co.
GBIO
|
13 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
375 K | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
1.7 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
2.42 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
2.91 M | $ 4.2 | -0.71 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
194 M | $ 293.87 | 0.19 % | $ 520 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
45.5 M | $ 151.6 | -3.2 % | $ 19.9 B | USA |
 |
Axon Enterprise
AXON
|
6.99 M | $ 302.6 | -0.19 % | $ 23.6 B | USA |
 |
Theratechnologies
THTX
|
383 K | - | - | $ 83.9 M | Canada |
 |
Liquidia Corporation
LQDA
|
1.03 M | $ 51.37 | 7.31 % | $ 4.42 B | USA |
 |
CRISPR Therapeutics AG
CRSP
|
18.6 M | $ 45.05 | -9.97 % | $ 4.05 B |  Schweiz |
 |
Scholar Rock Holding Corporation
SRRK
|
5.55 M | $ 48.48 | -5.96 % | $ 5.56 B | USA |
 |
Geron Corporation
GERN
|
1 M | $ 0.96 | -3.71 % | $ 640 M | USA |
 |
Bristol-Myers Squibb Company
BMY
|
202 M | $ 62.8 | 1.06 % | $ 128 B | USA |
 |
Titan Pharmaceuticals
TTNP
|
65 K | - | -3.76 % | $ 3.47 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
84 K | $ 7.4 | -0.13 % | $ 113 M |  Australia |
 |
Celldex Therapeutics
CLDX
|
1.55 M | $ 30.68 | -1.81 % | $ 2.04 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
814 K | $ 4.0 | -6.76 % | $ 48.8 M |  Israel |
 |
Allena Pharmaceuticals
ALNA
|
317 K | - | 3.16 % | $ 1.9 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
1.1 M | $ 317.26 | 0.99 % | $ 6.14 B | USA |
 |
TCR2 Therapeutics
TCRR
|
21.8 M | - | - | $ 58.1 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
6.49 M | $ 84.95 | 0.13 % | $ 7.99 B | USA |
|
TFF Pharmaceuticals
TFFP
|
83.5 K | - | -60.05 % | $ 125 K | USA |
 |
Mesoblast Limited
MESO
|
2.68 M | $ 14.0 | -3.06 % | $ 16.9 B | Australia |
 |
CorMedix
CRMD
|
853 K | $ 5.37 | -2.1 % | $ 387 K | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
4.71 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
MannKind Corporation
MNKD
|
2.11 M | $ 4.22 | 0.84 % | $ 1.29 B | USA |
 |
AVEO Pharmaceuticals
AVEO
|
11 K | - | - | $ 521 M | USA |
 |
MediciNova
MNOV
|
194 K | $ 1.4 | -4.76 % | $ 68.7 M | USA |
 |
Merck & Co.
MRK
|
294 M | $ 147.75 | -0.68 % | $ 370 B | USA |
 |
Moderna
MRNA
|
17 M | $ 250.79 | -6.77 % | $ 97.6 B | USA |
 |
Axcella Health
AXLA
|
1.59 M | - | -16.42 % | $ 249 M | USA |